Ocular Therapeutix (OCUL) Debt Ratio (2013 - 2026)
Ocular Therapeutix's quarterly Debt Ratio came in at 0.1 in Q1 2026, down 42.3% year-on-year from 0.17 in Q1 2025, and up 11.43% quarter-over-quarter from 0.09 in Q4 2025.
Ocular Therapeutix has reported Debt Ratio for 14 years, with the latest figure at 0.1 in Q1 2026.
- For the quarter ending Q1 2026, Debt Ratio fell 42.3% year-over-year to 0.1; the trailing twelve-month figure through Mar 2026 stood at 0.1 (down 42.3% YoY), and the FY2025 full-year result was 0.09, down 40.99% from the prior year.
- Debt Ratio for Q1 2026 stood at 0.1, up from 0.09 in the prior quarter.
- The five-year high for Debt Ratio was 0.4 in Q3 2023, with the low at 0.09 in Q4 2025.
- Average Debt Ratio over 5 years is 0.17, with a median of 0.15 recorded in 2025.
- Year-over-year, Debt Ratio soared 152.45% in 2023 and plunged 65.52% in 2024.
- Tracing OCUL's Debt Ratio over 5 years: stood at 0.17 in 2022, then surged by 54.27% to 0.26 in 2023, then slumped by 42.68% to 0.15 in 2024, then sank by 40.99% to 0.09 in 2025, then gained by 11.43% to 0.1 in 2026.
- The last three Debt Ratio figures came in at 0.1 (Q1 2026), 0.09 (Q4 2025), and 0.17 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.10 |
| Dec 31, 2025 | 0.09 |
| Sep 30, 2025 | 0.17 |
| Jun 30, 2025 | 0.15 |
| Mar 31, 2025 | 0.17 |
| Dec 31, 2024 | 0.15 |
| Sep 30, 2024 | 0.14 |
| Jun 30, 2024 | 0.13 |
| Mar 31, 2024 | 0.12 |
| Dec 31, 2023 | 0.26 |
| Sep 30, 2023 | 0.40 |
| Jun 30, 2023 | 0.19 |
| Mar 31, 2023 | 0.20 |
| Dec 31, 2022 | 0.17 |
| Sep 30, 2022 | 0.16 |
| Jun 30, 2022 | 0.15 |
| Mar 31, 2022 | 0.13 |
| Dec 31, 2021 | 0.12 |
| Sep 30, 2021 | 0.11 |
| Jun 30, 2021 | 0.11 |
| Mar 31, 2021 | 0.06 |
| Dec 31, 2020 | 0.06 |
| Sep 30, 2020 | 0.19 |
| Jun 30, 2020 | 0.20 |
| Mar 31, 2020 | 0.32 |
| Dec 31, 2019 | 0.32 |
| Sep 30, 2019 | 0.28 |
| Jun 30, 2019 | 0.28 |
| Mar 31, 2019 | 0.24 |
| Dec 31, 2018 | 0.34 |
| Sep 30, 2018 | 0.11 |
| Jun 30, 2018 | 0.14 |
| Mar 31, 2018 | 0.14 |
| Dec 31, 2017 | 0.22 |
| Sep 30, 2017 | 0.22 |
| Jun 30, 2017 | 0.19 |
| Mar 31, 2017 | 0.19 |
| Dec 31, 2016 | 0.19 |
| Sep 30, 2016 | 0.14 |
| Jun 30, 2016 | 0.14 |
| Mar 31, 2016 | 0.14 |
| Dec 31, 2015 | 0.14 |
| Sep 30, 2015 | 0.08 |
| Jun 30, 2015 | 0.08 |
| Mar 31, 2015 | 0.17 |
| Dec 31, 2014 | 0.17 |
| Sep 30, 2014 | 0.18 |
| Jun 30, 2014 | 0.57 |
| Dec 31, 2013 | 0.03 |